Repligen (RGEN)
(Delayed Data from NSDQ)
$122.30 USD
-2.08 (-1.67%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $122.21 -0.09 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RGEN 122.30 -2.08(-1.67%)
Will RGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGEN
Do Options Traders Know Something About Repligen Stock We Don't?
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
RGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repligen (RGEN) Lags Q2 Earnings Estimates
Here's Why Repligen (RGEN) is a Strong Growth Stock
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?
Other News for RGEN
RGEN Crossed Above 20 Day Moving Average on September 19
Is RGEN showing upside potential? Directional Movement Crossover Bullish shows up after sinking 0.3%
Regenera Inc. Announces Private Placement to Raise $236,192
Is RGEN likely to continue higher? Pocket Pivot shows up after rallying 5.28%
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Repligen (RGEN) and Exelixis (EXEL)